Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

biogen nz biopharma ltd - peginterferon beta-1a 94ug;  ; peginterferon beta-1a 63ug - solution for injection - active: peginterferon beta-1a 94ug   excipient: arginine hydrochloride glacial acetic acid polysorbate 20 sodium acetate trihydrate water for injection active: peginterferon beta-1a 63ug excipient: arginine hydrochloride glacial acetic acid polysorbate 20 sodium acetate trihydrate water for injection - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

biogen nz biopharma ltd - peginterferon beta-1a 125ug;   - solution for injection - 125 mcg/0.5ml - active: peginterferon beta-1a 125ug   excipient: arginine hydrochloride glacial acetic acid polysorbate 20 sodium acetate trihydrate water for injection - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis

Canada - Engels - Health Canada

biogen canada inc - peginterferon beta-1a - liquid - 63mcg - peginterferon beta-1a 63mcg - interferons

Canada - Engels - Health Canada

biogen canada inc - peginterferon beta-1a - liquid - 94mcg - peginterferon beta-1a 94mcg - interferons

Canada - Engels - Health Canada

biogen canada inc - peginterferon beta-1a - liquid - 125mcg - peginterferon beta-1a 125mcg - interferons

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

biogen idec ltd - peginterferon beta-1a - solution for injection - 250microgram/1ml

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

biogen idec ltd - peginterferon beta-1a - solution for injection - 126microgram/1ml

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

biogen idec ltd - peginterferon beta-1a - solution for injection - 188microgram/1ml

Verenigde Staten - Engels - NLM (National Library of Medicine)

genentech, inc. - peginterferon alfa-2a (unii: q46947fe7k) (peginterferon alfa-2a - unii:q46947fe7k) - peginterferon alfa-2a 180 ug in 1 ml - adult patients: pegasys, as part of a combination regimen with other hepatitis c virus (hcv) antiviral drugs, is indicated for the treatment of adults with chc and compensated liver disease. for information about the safe and effective use of other hcv antiviral drugs to be used in combination with pegasys, refer to their prescribing information. pegasys monotherapy is only indicated for the treatment of patients with chc and compensated liver disease if there are contraindications or significant intolerance to other hcv antiviral drugs. pediatric patients: pegasys in combination with ribavirin is indicated for the treatment of pediatric patients 5 years of age and older with chc and compensated liver disease. limitations of use : - pegasys alone or in combination with ribavirin without additional hcv antiviral drugs is not recommended for treatment of patients with chc who previously failed therapy with an interferon-alfa. - pegasys is not recommended for treatment of patients with chc who have had solid

Verenigde Staten - Engels - NLM (National Library of Medicine)

merck sharp & dohme corp. - peginterferon alfa-2b (unii: g8rgg88b68) (peginterferon alfa-2b - unii:g8rgg88b68) - peginterferon alfa-2b 40 ug in 0.1 ml - sylatron™ is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy. sylatron is contraindicated in patients with: - a history of anaphylaxis to peginterferon alfa-2b or interferon alfa-2b - autoimmune hepatitis - hepatic decompensation (child-pugh score >6 [class b and c]) risk summary based on findings from animal studies, sylatron can cause embryo-fetal harm when administered to a pregnant woman. available human data with sylatron use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. administration of nonpegylated interferon alfa-2b was abortifacient in rhesus monkeys at doses approximately 13 times higher than the recommended dose of 6 mcg/kg/week (see data ). in the u.s. general population, the estimated background risk of major birth defects and miscarriage is 2-4% and